Molecular Aspects of Medicine

ISSN 0098-2997 · Elsevier BV · United Kingdom · active 1976–2026

Metrics

Scimago quartile
Q1
Cites per paper (2y)
8.3
SJR
3.427
h-index
194

“Cites per paper” is a two-year cited-by rate computed from OpenAlex. It is not a Clarivate Journal Impact Factor — we neither compute nor license that metric. Citation rates differ enormously between fields, so compare within a discipline.

Indexing & access

ScopusWeb of SciencePubMed

Access status: unknown. Where this comes from publisher-level signals rather than works-level data it is a heuristic — confirm on the journal’s own site, especially regarding any article processing charge.

Scope

diverseeconomiceconomicseconometricshumanauditoryperceptionevaluationaerospaceengineeringeducationalrobotics

Frequently asked

Is Molecular Aspects of Medicine a predatory journal?

Our screening does not flag Molecular Aspects of Medicine. That is not a guarantee of quality — it means the venue is not on Beall's archive (frozen since 2017) and does not match our name-pattern heuristic. It is listed in Scopus, Web of Science, PubMed, which is a positive signal.

Is Molecular Aspects of Medicine indexed in Scopus or Web of Science?

Per our venue index, Molecular Aspects of Medicine appears in: Scopus, Web of Science, PubMed. Index membership changes over time — confirm on the index's own site before relying on it.

What is Molecular Aspects of Medicine's impact?

Papers in Molecular Aspects of Medicine are cited about 8.3 times each within two years of publication, and Scimago places it in Q1, with an h-index of 194. This is not a Clarivate Journal Impact Factor — we neither compute nor license that metric — and a citation rate is a property of a field as much as of a journal.

Is Molecular Aspects of Medicine open access?

We hold no reliable open-access classification for Molecular Aspects of Medicine. Check the journal's own site for its access model and any article processing charge.

Similar venues

Command palette

Jump anywhere, run any action.